Progenics Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference

Progenics Pharmaceuticals to Present at Lazard Capital Markets Healthcare

TARRYTOWN, N.Y., Nov. 6, 2012 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals,
Inc. (Nasdaq:PGNX) chief executive officer Mark R. Baker will make a
presentation on Tuesday, November 13 at 3:30 PM EST at the Lazard Capital
Markets 9th Annual Healthcare Conference in New York City. Mr. Baker will
provide a company overview, which will be webcast live via a link on the
Events page of Progenics' website, and archived there for 90 days.

About Progenics

Progenics Pharmaceuticals, Inc., of Tarrytown, N.Y., is a biopharmaceutical
company dedicated to developing innovative medicines to treat disease, with a
focus on cancer and related conditions. Progenics' pipeline candidates include
PSMA ADC, a human monoclonal antibody-drug conjugate in phase 2 testing for
treatment of prostate cancer, and preclinical stage novel multiplex
phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer.
Progenics has exclusively licensed development and commercialization rights
for its first commercial product, Relistor^®, to Salix Pharmaceuticals, Ltd.
for markets worldwide other than Japan, where Ono Pharmaceutical Co., Ltd.
holds an exclusive license for the subcutaneous formulation. Relistor
(methylnaltrexone bromide) subcutaneous injection is a first-in-class
treatment for opioid-induced constipation approved in more than 50 countries
for patients with advanced illness. For more information, please visit

Additional information concerning Progenics and its business may be available
in press releases or other announcements and public filings made after this

The Progenics Pharmaceuticals Inc. logo is available at


CONTACT: Amy Martini
         Corporate Affairs
         (914) 789-2816

company logo
Press spacebar to pause and continue. Press esc to stop.